MedTrace Logo

Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention

NCT02067104 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-08-14

Study results available
· View outcomes & findings →

Summary

This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).

Conditions

  • Basal Cell Carcinomas

Interventions

DRUG

Vismodegib

Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.

DRUG

Placebo

Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.

Sponsors & Collaborators

  • University of Arizona

    lead OTHER

Principal Investigators

  • Clara Curiel-Lewandroski · University of Arizona

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-17
Primary Completion
2016-12-31
Completion
2016-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02067104 on ClinicalTrials.gov